Your session is about to expire
← Back to Search
Olaparib for Cancer
Study Summary
This trial is testing how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in DNA damage repair genes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 3 trial • 154 Patients • NCT02184195Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your kidneys are working well, with a filtration rate of at least 70 ml/min/1.73 m^2.I do not have symptoms of Fanconi anemia, ataxia-telangiectasia, Bloom syndrome, or Nijmegen breakage syndrome.I have active hepatitis B or C.I have recovered from previous cancer treatments and meet the required waiting period.I have received radiopharmaceutical therapy.I am between 12 and 21 years old.I am taking other medications.I do not have any infections that are currently uncontrolled.I have brain metastases that are causing symptoms and are not under control.I have not had major surgery in the last 2 weeks or am fully recovered from it.I am enrolled in APEC1621SC and assigned to MATCH based on a specific mutation.My cancer can be seen and measured on scans, or it shows up on special scans for neuroblastoma.I am mostly able to care for myself, regardless of my age.I have received external beam radiation therapy.My white blood cell count is healthy for cancer treatment.I have received a stem cell infusion, with or without total body irradiation.You have had an organ transplant in the past.My body surface area is at least 0.65 square meters.I have never taken PARP inhibitors like olaparib or rucaparib.You have tested positive for human immunodeficiency virus (HIV).
- Group 1: Treatment (olaparib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Olaparib been granted official sanction by the Food and Drug Administration?
"The safety profile of Olaparib is rated a 2 on our scale, since this Phase 2 trial has evidence of safety but no data yet verifying its efficacy."
Is the age cutoff for this research project restricted to those below 40 years of age?
"The present investigation is accepting individuals aged between one and twenty-one years old."
How many participants are engaging in this research program?
"This trial has since closed recruiting, with its initial post on July 24th 2017 and latest update being October 18th 2022. Fortunately, there are still 5674 clinical trials for rhabdoid tumor looking to admit patients and 188 studies pertaining to Olaparib in search of subjects."
Is this clinical trial currently accepting volunteers?
"This trial is no longer open for enrollment, with the study first posted on July 24th 2017 and last updated October 18th 2022. For those seeking alternatives, there are currently 5674 trials looking to recruit participants dealing with rhabdoid tumors and 188 studies actively recruiting patients who require Olaparib treatment."
How many facilities in Canada are currently conducting this investigation?
"This clinical trial has 100 spots available at various medical centres, including Carolinas Medical Center/Levine Cancer Institute in Charlotte, Sanford USD Medical Center - Sioux Falls in Sioux Falls and Saint Jude Children's Research Hospital in Memphis. Additionally, there are a plethora of other sites providing slots for this study."
Is this a pioneering clinical trial?
"Currently, 188 trials involving Olaparib are active across 1468 cities and 59 countries. This medication's journey began in 2005 with a Phase 1 trial sponsored by AstraZeneca; this study enrolled 98 patients and was finished successfully. As of now, 63 studies have been concluded since the initial experiment 15 years ago."
Has Olaparib been subject to previous research?
"Olaparib was initially tested in 2005 at Research Site. Since then, 63 investigations have been concluded, with 188 currently ongoing trials largely located near Charlotte, North carolina."
What is the typical application of Olaparib?
"Olaparib is an efficacious remedy for advanced cases and has been known to ease the symptoms of malignancies in ovaries, primary peritoneal cancer, phantom sensations, and physical manifestations."
Are there specific criteria that must be met in order to participate in this medical experiment?
"For qualification, applicants must have a rhabdoid tumor and be between 12 months to 21 years of age. Additionally, they need to possess radiographically measurable disease at the time of enrolment or an iobenguane (MIBG) positive (+) evaluable illness for neuroblastoma sufferers. Other criteria include malignant fluid collections (e.g., ascites, pleural effusions), bone marrow infiltration except that detected by MIBG scan for neuroblastoma and lesions only detectable on nuclear medicine studies such as gallium scans and PET scans). The participants’ body surface area should also exceed 0.65 m"
Share this study with friends
Copy Link
Messenger